Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause

• Status: Completed
• Trial end date: 2007-03-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to determine whether Bazedoxifine/conjugated estrogens are effective in the treatment of vaginal atrophy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
• Treatments: Bazedoxifene; Estrogens; Estrogens, Conjugated (USP)

Criteria

Inclusion Criteria:

• Generally healthy, postmenopausal women, aged 40 to 65 years

• Intact uterus

• At least 1 moderate to severe vulvar/vaginal symptom that is most bothersome

Exclusion Criteria:

• Hypersensitivity to estrogens, endometrial hyperplasia, known or suspected estrogen-dependent neoplasia

• Thrombophlebitis, thrombosis or thromboembolic disorders

• Neuro-ocular disease